

Table 2. Univariable and multivariable analyses: association of patient, tumor, and treatment characteristics with overall survival.

	Univariable analyses		Multivariable analyses	
	Hazard ratio [95%-CI]	p-value	Hazard ratio [95%-CI]	p-value
Age (years)				
<40 (reference)				
40-59	0.9 [0.8 – 1.0]	0.085	1.0 [0.8 – 1.1]	0.416
≥60	1.4 [1.2 – 1.6]	<0.001	1.3 [1.1 – 1.5]	<0.001
Molecular subtype				
HR+, HER2- (reference)				
HR+, HER2+	0.7 [0.6 – 0.8]	<0.001	1.0 [0.9 – 1.2]	0.968
HR-, HER2+	1.4 [1.2 – 1.6]	<0.001	2.0 [1.7 – 2.3]	<0.001
Triple negative	2.6 [2.4 – 2.8]	<0.001	3.3 [3.0 – 3.7]	<0.001
Grade				
1 (reference)				
2	1.5 [1.1 – 1.9]	0.003	1.5 [1.1 – 1.9]	0.004
3	3.1 [2.4 – 4.1]	<0.001	2.7 [2.0 – 3.6]	<0.001
cT-status				
cT1-2 (reference)				
cT3-4	2.4 [2.2 – 2.6]	<0.001	1.6 [1.4 – 1.7]	<0.001
cN-status				
cN0 (reference)				
cN1	2.3 [2.1 – 2.6]	<0.001	1.1 [1.0 – 1.3]	0.036
cN2	3.7 [3.0 – 4.5]	<0.001	1.6 [1.3 – 2.0]	<0.001
cN3	4.3 [3.7 – 4.9]	<0.001	1.7 [1.4 – 2.0]	<0.001
Breast surgery				
BCS (reference)				
Mastectomy	2.5 [2.2 – 2.7]	<0.001	1.5 [1.4 – 1.7]	<0.001
ypT-status				
ypT0/is (reference)				
ypT+	2.3 [2.0 – 2.6]	<0.001	2.1 [1.9 – 2.4]	<0.001
ALND				
No (reference)				
Yes	3.5 [3.2 – 3.9]	<0.001	1.8 [1.6 – 2.0]	<0.001
ypN-status				
ypN0 (reference)				
ypN+	3.0 [2.8 – 3.3]	<0.001	2.3 [2.0 – 2.6]	<0.001

ALND, axillary lymph node dissection; BCS, breast-conserving surgery; CI, confidence interval; cN0, node-negative before NAC; HER2, human epidermal growth factor 2; HR, hormone receptor; ypN0, absence of nodal disease; ypN+, presence of nodal disease; ypT0/is (or breast pCR), absence of invasive primary tumor, irrespective of whether or not in situ carcinoma was present; ypT+ (or no breast pCR), presence of invasive primary tumour.

One hundred and eighty-five patients were excluded from these analyses since they had cTX or cTis disease at diagnosis, 776 patients were excluded since they had an unknown ypT-status, and 3,709 patients were excluded since they underwent sentinel lymph node biopsy before neoadjuvant chemotherapy.